Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more
Corline Biomedical AB (CLBIO) - Total Assets
Latest total assets as of September 2025: Skr82.31 Million SEK
Based on the latest financial reports, Corline Biomedical AB (CLBIO) holds total assets worth Skr82.31 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Corline Biomedical AB - Total Assets Trend (2012–2024)
This chart illustrates how Corline Biomedical AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Corline Biomedical AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Corline Biomedical AB's total assets of Skr82.31 Million consist of 22.2% current assets and 77.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr17.67 Million | 18.6% |
| Accounts Receivable | Skr2.63 Million | 2.8% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr219.00K | 0.2% |
| Intangible Assets | Skr73.50 Million | 77.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Corline Biomedical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corline Biomedical AB's current assets represent 22.2% of total assets in 2024, a decrease from 28.8% in 2012.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2024, down from 18.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 77.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 77.6% of total assets.
Corline Biomedical AB Competitors by Total Assets
Key competitors of Corline Biomedical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Corline Biomedical AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Corline Biomedical AB generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Corline Biomedical AB is currently not profitable relative to its asset base.
Corline Biomedical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.14 | 1.72 |
| Quick Ratio | 1.52 | 1.14 | 1.72 |
| Cash Ratio | 1.14 | 0.86 | 0.00 |
| Working Capital | Skr2.65 Million | Skr 1.20 Million | Skr 4.49 Million |
Corline Biomedical AB - Advanced Valuation Insights
This section examines the relationship between Corline Biomedical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.20 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | Skr94.76 Million |
| Market Capitalization | $10.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Corline Biomedical AB's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Corline Biomedical AB's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Corline Biomedical AB (2012–2024)
The table below shows the annual total assets of Corline Biomedical AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr94.76 Million | -5.34% |
| 2023-12-31 | Skr100.11 Million | -1.65% |
| 2022-12-31 | Skr101.78 Million | +0.12% |
| 2021-12-31 | Skr101.66 Million | +74.43% |
| 2020-12-31 | Skr58.28 Million | -8.58% |
| 2019-12-31 | Skr63.75 Million | +1.33% |
| 2018-12-31 | Skr62.91 Million | +22.34% |
| 2017-12-31 | Skr51.43 Million | +24.60% |
| 2016-12-31 | Skr41.27 Million | +65.13% |
| 2015-12-31 | Skr24.99 Million | +49.02% |
| 2014-12-31 | Skr16.77 Million | +21.92% |
| 2013-12-31 | Skr13.76 Million | +10.41% |
| 2012-12-31 | Skr12.46 Million | -- |